Study S000602

A Single Centre, Open Label Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02060266
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 7
Start: 2014-02-04
Primary completion: 2014-04-28
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Healthy
Interventions: DRUG:semaglutide
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2013-001769-18; OTHER:U1111-1142-0810

Registered primary outcomes

Concentration of the major metabolites of [3H]-semaglutide in plasma, urine, and faeces [Up to 9 weeks following a single dose of 0.5 mg [3H]-semaglutide]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0018024	Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Jensen L, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences	2017	Preclinical	PMID 28323117 DOI	registry reference RESULT:28323117